Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-22
2005-03-22
Sisson, Bradley L. (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S012200, C514S925000, C435S069100, C435S069400, C435S243000, C435S320100, C435S325000, C530S300000, C530S324000, C530S328000, C530S399000, C530S402000, C536S023510
Reexamination Certificate
active
06869927
ABSTRACT:
The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5677278 (1997-10-01), Gospodarowicz et al.
patent: 5703047 (1997-12-01), Wilson
patent: 5731170 (1998-03-01), Rubin et al.
patent: 5773252 (1998-06-01), Greene et al.
patent: 5773586 (1998-06-01), Gospodarowicz et al.
patent: 5814605 (1998-09-01), Pierce et al.
patent: 5824643 (1998-10-01), Pierce et al.
patent: 5843883 (1998-12-01), Gospodarowicz et al.
patent: 5863767 (1999-01-01), Gospodarowicz et al.
patent: 6077692 (2000-06-01), Ruben et al.
patent: 6238888 (2001-05-01), Gentz et al.
patent: 0 619 370 (1994-10-01), None
patent: 2 321 852 (1998-08-01), None
patent: 7-345689 (1995-12-01), None
patent: 8-103240 (1996-03-01), None
patent: 8-214378 (1996-07-01), None
patent: 10-330283 (1998-12-01), None
patent: 10-330284 (1998-12-01), None
patent: 10-330285 (1998-12-01), None
patent: WO 9008771 (1900-08-01), None
patent: WO 9214480 (1992-09-01), None
patent: WO 9222304 (1992-12-01), None
patent: WO 9321908 (1993-11-01), None
patent: WO 9422427 (1994-10-01), None
patent: WO 9423032 (1994-10-01), None
patent: WO 9501434 (1995-01-01), None
patent: WO 9503831 (1995-02-01), None
patent: WO 9524928 (1995-09-01), None
patent: WO 9524928 (1995-09-01), None
patent: WO 9611949 (1996-04-01), None
patent: WO 9611950 (1996-04-01), None
patent: WO 9611951 (1996-04-01), None
patent: WO 9611952 (1996-04-01), None
patent: WO 9622369 (1996-07-01), None
patent: WO 9625422 (1996-08-01), None
patent: WO 9720929 (1997-12-01), None
patent: WO 9806844 (1998-02-01), None
patent: WO 9816243 (1998-04-01), None
patent: WO 9816642 (1998-04-01), None
patent: WO 9932135 (1999-07-01), None
patent: WO 9941282 (1999-08-01), None
patent: WO 0072872 (2000-12-01), None
patent: WO 0102433 (2001-01-01), None
Pending Non-Provisional U.S. patent application Ser. No. 10/194,443, Laird, M.W., filed Jul. 12, 2002 (Not Published).
English language translation of Japanese Patent Application Publication No. 10-330283, Sumitomo Seiyaku Corp., Ltd., filed May 30, 1997 and published Dec. 15, 1998 (Document AP5).
English language translation of Japanese Patent Application Publication No. 10-330284, Sumitomo Seiyaku Corp., Ltd., filed May 30, 1997 and published Dec. 15, 1998 (Document AL6).
English language translation of Japanese Patent Application Publication No. 10-330285, Sumitomo Seiyaku Corp., Ltd., filed May 30, 1997 and published Dec. 15, 1998 (Document AM6).
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science 247:1306-1310, American Association for the Advancement of Science (1990).
Finch, P.W., et al., “Human KGF Is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth,”Science 245:752-755, American Association for the Advancement of Science (1989).
Hartung, H., et al., “Murine FGF-12 and FGF-13: expression in embryonic nervous sytem, connective tissue and heart,”Mech. Dev. 64:31-39, Elsevier Science Ireland Ltd. (Jun. 1997).
Hartung, H., et al., “Assignment of Fgf12 to mouse chromosome bands 16B1→B3 in situ hybridization,”Cytogenet. Cell Genet. 76:185-186, Karger A.G. (Apr. 1997).
Jimenez, P., et al., “Effect of Topical Keratinocyte Growth Factor-2 on Wound Healing In A Glucocorticoid-Impaired Model,”J. Cutan. Pathol. 24:105, Munksgaard (Feb. 1997).
Jimenez, P.A., et al., “Effect of Keratinocyte Growth Factor-2 on Cell Proliferation In Vivo,”FASEB J. 11:A523, Abstract No. 3025, Federation of American Societies for Experimental Biology (Apr. 1997).
Jimenez, P.A. and Rampy, M.A., “Keratinocyte Growth Factor-2 Accelerates Wound Healing in Incisional Wounds,”J. Surg. Res. 81:238-242, Academic Press, Inc. (Feb. 1999).
Kelley, M.J., et al., “Emergence of the keratinocyte growth factor multigene family during the great ape radiation,”Proc. Natl. Acad. Sci. USA 89:9287-9291, National Academy of Sciences (1992).
Mason, I.J., et al., “FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions,”Mech. Dev. 45:15-30, Elsevier Science Ireland Ltd. (Jan. 1994).
Miyamoto, M., et al., “Molecular Cloning of a Novel Cytokine cDNA Encoding the Ninth Member of the Fibroblast Growth Factor Family, Which Has a Unique Secretion Property,”Mol. Cell. Biol. 13:4251-4259, American Society for Microbiology (1993).
Ngo, J.T., et al, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” in:The Protein Folding Problem and Tertiary Structure Prediction,Merz, Jr., K. and Le Grand, S., eds., Birkhauser, Boston, Massachusetts, pp. 491-495 (1994).
Robson, B. and Garnier, J., “Modern ideas and notations relating to primary structure,” in:Introduction to Proteins and Protein Engineering,Robson, B. and Garnier, J., eds., Elsevier Science, Amsterdam, The Netherlands, p. 41 (1986).
Ron, D., et al., “Expression of Biologically Active Recombinant Keratinocyte Growth Factor,”J. Biol. Chem. 268:2984-2988, American Society for Biochemistry and Molecular Biology, Inc. (1993).
Wells, J.A., “Additivity of Mutational Effects in Proteins,”Biochem. 29:8509-8517, American Chemical Society, (1990).
Yamasaki, M., et al., “Structure and Expression of the Rat mRNA Encoding a Novel Member of the Fibroblast Growth Factor Family,”J. Biol. Chem. 271:15918-15921, American Society for Biochemistry and Molecular Biology, Inc. (Jul. 1996).
Yan, G., et al., “Sequence of Rat Keratinocyte Growth Factor (Heparin-Binding Growth Factor Type 7),”In Vitro Cell. Dev. Biol. 27A:437-438, Tissue Culture Association (1991).
NCBI Entrez, GenBank Report with Revision History, Accession No. M79878, McCombie, W.R. et al., National Center for Biotechnology Information (1992).
NCBI Entrez, GenBank Report with Revision History, Accession No. T52063, Hillier, L. et al., National Center for Biotechnology Information (Feb. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D46201, Sasaki, T. et al., National Center for Biotechnology Information (Aug. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D46420, Sasaki, T. et al., National Center for Biotechnology Information (Aug. 995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D54216, Fujiwara, T. et al., National Center for Biotechnology Information (Sep. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D68729, Kohara, Y. et al., National Center for Biotechnology Information (Dec. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D69248, Kohara, Y. et al., National Center for Biotechnology Information (Dec. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D65627, Kohara, Y. et al., National Center for Biotechnology Information (Dec. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. D66221, Kohara, Y. et al., National Center for Biotechnology Information (Dec. 1995).
NCBI Entrez, GenBank Report with Revision History, Accession No. C02000, Okubo, K., National Center for Biotechnology Information (Jul. 1996).
NCBI Entrez, GenBank Report with Revision History, Accession No. W29377, Marra, M. et al., National Center for Biotechnology Information (Sep. 1996).
NCBI Entrez, GenBank Report with Revision History, Accession No. W32720, Hillier, L. et al., National Center for Biotechnology Information (Oct. 1996).
NCBI Entrez, GenBank Report with Revision History, Accession No. W60824, Hillier, L. et al., National Center for Biotechnology Information (Oct. 1
Chopra Arvind
Gentz Reiner L.
Kaushal Parveen
Khan Fazal
Spitznagel Thomas
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Sisson Bradley L.
LandOfFree
Keratinocyte growth factor-2 formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Keratinocyte growth factor-2 formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Keratinocyte growth factor-2 formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431936